- Coding & Pricing
National Drug Codes (NDCs)
NDCs help physicians and payors identify specific product package sizes. FRAGMIN® (dalteparin sodium injection) is available in single-dose prefilled syringes, single-dose graduated syringes, and multiple dose vials:
|FRAGMIN® Package Size||NDC1|
|Single-dose prefilled syringe (10 syringes per package)|
|2,500 IU / 0.2 mL||62856-250-10|
|5,000 IU / 0.2 mL||62856-500-10|
|7,500 IU / 0.3 mL||62856-750-10|
|12,500 IU / 0.5mL||62856-125-10|
|15,000 IU / 0.6 mL||62856-150-10|
|18,000 IU / 0.72mL||62856-180-10|
|Single-dose graduated syringe (10 syringes per package)|
|10,000 IU / 1 mL||62856-101-10|
|Multiple dose vial|
|95,000 IU / 3.8 mL||62856-251-01|
Some payors require physicians to report 11-digit NDCs when reporting a drug on a claim form. Converting the 10-digit NDC for FRAGMIN® to an 11-digit NDC requires the use of a leading zero in the product code section of the NDC (ie, the middle section).
|10-Digit NDC Example||11-Digit NDC Example With Leading Zero|
|Example FRAGMIN® 10-Digit NDC||Example FRAGMIN® 11-Digit NDC with Leading Zero|
For more information on payor specific policies and other questions contact your health plan.
1. 2010 ICD-9-CM for Physicians, Volumes 1 & 2, Professional Edition.
FRAGMIN® is a low molecular weight heparin (LMWH) indicated for:
- Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction
- Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness
- Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in patients with cancer. In these patients, the FRAGMIN® therapy begins with the initial VTE treatment and continues for six months.
Limitations of Use
- FRAGMIN® is not indicated for the acute treatment of VTE.
Important Safety Information
Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
- Use of indwelling epidural catheters
- Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
- A history of traumatic or repeated epidural or spinal punctures
- A history of spinal deformity or spinal surgery
- Optimal timing between the administration of FRAGMIN® and neuraxial procedures is not known
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.
- FRAGMIN® is contraindicated in patients with active major bleeding, history of heparin induced thrombocytopenia, hypersensitivity to dalteparin sodium, heparin, or pork products.
- FRAGMIN® is contraindicated in patients undergoing epidural/neuraxial anesthesia as a treatment for unstable angina and non-Q-wave MI and for prolonged VTE prophylaxis due to an increased risk of bleeding associated with the dosage of FRAGMIN® recommended for these indications.
- FRAGMIN®, like other anticoagulants, should be used with extreme caution in patients who have an increased risk of hemorrhage; bleeding can occur at any site during therapy. An unexpected drop in hematocrit or blood pressure should lead to a search for a bleeding site.
- The optimal timing between the administration of FRAGMIN® and neuraxial
procedures is not known. To reduce the potential risk of bleeding associated with
concurrent use of FRAGMIN® and epidural or spinal anesthesia/analgesia
or spinal puncture, consider the pharmacokinetic profile of FRAGMIN®.
- Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture, frequent monitoring must be exercised to detect any signs and symptoms of neurological impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), bowel and/or bladder dysfunction. Instruct patients to report immediately if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae.
- FRAGMIN® should be used with caution in patients with bleeding diathesis, thrombocytopenia or platelet defects, severe liver or kidney insufficiency, hypertensive or diabetic retinopathy, and recent gastrointestinal bleeding.
- FRAGMIN® should be used with extreme caution in patients
with history of heparin-induced thrombocytopenia.
- In FRAGMIN® clinical trials supporting non-cancer indications, platelet count of <50,000/mm3 occurred in <1% of patients.
- In FRAGMIN® clinical trials supporting the extended treatment of symptomatic VTE in patients with cancer, platelet counts of <100,000/mm3 occurred in 13.6% of patients, including 6.5% who also had platelet counts less than 50,000/mm3. In the same clinical trial, thrombocytopenia was reported as an adverse event in 10.9% of patients in the FRAGMIN® arm and 8.1% of patients in the oral anticoagulant arm. FRAGMIN® dose was decreased or interrupted in patients whose platelet counts fell below 100,000/mm3.
- Thrombocytopenia of any degree should be monitored closely. Heparin-induced thrombocytopenia can occur with administration of FRAGMIN®. The incidence of this complication is unknown at present. In clinical practice, rare cases of thrombocytopenia with thrombosis have also been observed.
- Each multiple-dose vial of FRAGMIN® contains benzyl alcohol as a preservative. Benzyl alcohol has been reported to be associated with a fatal “Gasping Syndrome” in premature infants. Because benzyl alcohol may cross the placenta, use caution when administering FRAGMIN® preserved with benzyl alcohol to pregnant women. If anticoagulation with FRAGMIN® is needed during pregnancy, use preservative-free formulations, where possible.
- Periodic routine complete blood counts, including platelet count, blood chemistry, and stool occult blood tests are recommended during the course of treatment with FRAGMIN®. Anti-Factor Xa may be used to monitor the anticoagulant effect of FRAGMIN®, such as in patients with severe renal impairment or if abnormal coagulation parameters or bleeding occurs during FRAGMIN® therapy.
- The most commonly reported side effect is hematoma at the injection site.
- Allergic reactions (i.e., pruritus, rash, fever, injection site reaction, bulleous eruption) have occurred. A few cases of anaphylactoid reactions have been reported.
- Use FRAGMIN® with care in patients receiving oral anticoagulants, platelet inhibitors, and thrombolytic agents because of increased risk of bleeding.
- FRAGMIN® cannot be used interchangeably (unit for unit) with unfractionated heparin or other low molecular weight heparins.
- FRAGMIN® Injection is not intended for intramuscular administration.
For more information about FRAGMIN®, please see Full Product Information.